While coronavirus disease 2019 (COVID-19) is largely a respiratory disease, it is actually a systemic disease that has a wide range of effects and postinfection sequelae that aren’t yet fully known, said Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.
While coronavirus disease 2019 (COVID-19) is largely a respiratory disease, it is actually a systemic disease that has a wide range of effects and postinfection sequelae that aren’t yet fully known, said Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.
Transcript
There seems to be a range of symptoms for COVID-19, with some people getting blood clots and neurological symptoms, and then a minority of children are coming down with an autoimmune syndrome. Do you think this will always remain a respiratory disease or do you think it might someday become a systemic disease for some people?
Well, I think it already is a systemic disease for some people—we’re just not recognizing the full implications of the pathogenesis and the clinical manifestations. I mean, I don't think it necessarily is going to evolve to do more systemically, but I think what we'll likely see are more surprises like the multisystem inflammatory disease in children—MIS-C. I think we likely will see as time goes by some postinfection sequelae that we'll only realize as we do good follow up in natural history studies.
I mean, the scope of the seriousness of this infection is extraordinary—from people who get a stuffy nose and a little sore throat and ache, and they get better to people who spend 14 days with a sustained fever and come out wiped out with a postviral dystonia, to people who have serious lung involvement that either puts them in the hospital or creates intubation needs and intensive care…to people who die.
I mean, that range of severity is really in many respects unprecedented. So, I think we still have a lot to learn about the disease of COVID-19.
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More